TREA

97593502 - SLOREL

Follow

Information

  • Trademark
  • 97593502
  • Serial Number
    97593502
  • Filing Date
    September 15, 2022
    2 years ago
  • Transaction Date
    August 13, 2024
    a month ago
  • Status Date
    March 12, 2024
    6 months ago
  • Location Date
    March 12, 2024
    6 months ago
  • Status Code
    654
  • Current Location
    TMO LAW OFFICE 112 - EXAMINING ATTORNEY ASSIGNED
    Employee Name
    SAXTON, EVELYN H
  • Attorney Docket Number
    8772CG-2
    Attorney Name
    Miriam D. Trudell
    Law Office Assigned Location Code
    M30
  • Owners
Information
Mark Drawing Code
4
Mark Identification
SLOREL
Case File Statements
  • GS0051: Surgical implants comprised of living tissues for guided tissue regeneration; implants comprising living tissue; implantable materials for use in guided tissue regeneration in the nature of implants comprising living tissue; Surgical implants comprised of living tissues used in transplants, namely, vascular grafts being living tissue and human allograft tissue; surgical implants comprised of living tissues; human allograft tissue; bone void fillers comprised of living tissues; Stem cells for medical purposes, namely, surgical implants grown from stem cells; pharmaceutical preparations for use in tissue transplantation; tissue-regenerative pharmaceutical preparations; medicines for human purposes, namely, pharmaceutical preparations for the treatment of musculo-skeletal disorders; medicines for human purposes, namely, a drug delivery system comprising liquids, powders, tablets or capsules for the continuous release of a wide variety of therapeutic agents, namely, pharmaceutical preparations for the treatment of musculo-skeletal disorders; drugs for medical purposes, namely, drugs for use in bioregenerative procedures, drugs for use for regenerative purpose, drugs for use to assist with artificial bone growth, drugs for use in accelerating bone formation, drugs for use to stimulate new bone formation; pharmaceutical agents affecting sensory organs; pharmaceutical preparations for the prevention of diseases of the musculo- skeletal system; pharmaceutical preparations for the treatment of Musculo-skeletal disorders; cellular function activating agents for medical purposes; pharmaceutical preparations for use in organ transplantation; biological tissue cultures for medical purposes; drug delivery agents in the form of liquid, powders, tablets and capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of dissolvable films added to bone substitutes; drug delivery agents in the form of dissolvable films for use in bioregenerative procedures; drug delivery agents in the form of dissolvable films that provide sustained release of drugs for use with implants and bone substitutes; drug delivery agents in the form of drug delivery compounds that facilitate sustained or extended release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of dissolvable films with controlled timing and rate of drug release; medicines for human use, namely pharmaceutical preparations for the treatment of musculo-skeletal disorders featuring controlled timing and rate of release; medical bone graft substitute, namely, biological tissue bone grafts; medical bone graft materials, namely, bone fillers consisting of living materials; medical bone graft materials with drug release function being bone growth media consisting of biological materials for medical bone graft purposes with drug release function; medical bone graft materials, namely, biological bone tissue intended for subsequent implantation in a bone graft with drug release function, that provide sustained release of drugs for use with implants and bone substitutes; medical bone graft materials being biological bone tissue intended for subsequent implantation with drug release function that are sold filled with pharmaceutical preparations used with implants and bone substitutes
Case File Event Statements
  • 9/19/2022 - 2 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 10/1/2022 - a year ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 3/14/2023 - a year ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 4/14/2023 - a year ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 4/14/2023 - a year ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 4/14/2023 - a year ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 5/12/2023 - a year ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 5/12/2023 - a year ago
    8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 5/12/2023 - a year ago
    9 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 1/17/2024 - 8 months ago
    13 - SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Type: RCCK
  • 3/12/2024 - 6 months ago
    14 - REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED Type: RCSC
  • 8/13/2024 - a month ago
    15 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI
  • 6/16/2023 - a year ago
    10 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 6/16/2023 - a year ago
    11 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 6/16/2023 - a year ago
    12 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3